KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 160 filers reported holding KARYOPHARM THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.79 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $1,185,630 | +258.3% | 662,363 | +580.5% | 0.00% | – |
Q4 2022 | $330,943 | +308.6% | 97,336 | +559.1% | 0.00% | – |
Q3 2022 | $81,000 | -91.4% | 14,768 | -92.9% | 0.00% | – |
Q2 2022 | $941,000 | -81.8% | 208,597 | -70.3% | 0.00% | -100.0% |
Q1 2022 | $5,169,000 | +123.2% | 701,443 | +94.8% | 0.00% | – |
Q4 2021 | $2,316,000 | +442.4% | 360,143 | +391.1% | 0.00% | – |
Q3 2021 | $427,000 | -35.4% | 73,328 | +14.5% | 0.00% | – |
Q2 2021 | $661,000 | -46.4% | 64,042 | -45.4% | 0.00% | – |
Q1 2021 | $1,233,000 | -59.4% | 117,225 | -40.3% | 0.00% | -100.0% |
Q4 2020 | $3,039,000 | +50.5% | 196,358 | +42.0% | 0.00% | +100.0% |
Q3 2020 | $2,019,000 | -63.0% | 138,325 | -52.0% | 0.00% | -80.0% |
Q2 2020 | $5,457,000 | +111.7% | 288,119 | +114.7% | 0.01% | +66.7% |
Q1 2020 | $2,578,000 | +801.4% | 134,200 | +798.4% | 0.00% | – |
Q4 2019 | $286,000 | +38.8% | 14,937 | -30.3% | 0.00% | – |
Q3 2019 | $206,000 | -68.7% | 21,423 | +51.6% | 0.00% | -100.0% |
Q2 2014 | $658,000 | – | 14,132 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Consonance Capital Management LP | 4,767,078 | $80,993,000 | 5.22% |
Palo Alto Investors LP | 4,663,324 | $79,230,000 | 3.17% |
DOHENY ASSET MANAGEMENT /CA | 282,945 | $4,807,000 | 2.61% |
Private Capital Advisors, Inc. | 416,900 | $7,083,000 | 2.22% |
Sandia Holdings, LLC | 119,739 | $2,034,000 | 0.91% |
Virtus ETF Advisers LLC | 44,986 | $764,000 | 0.68% |
Birchview Capital, LP | 50,000 | $850,000 | 0.58% |
Schonfeld Strategic Advisors LLC | 415,600 | $7,061,000 | 0.38% |
EMERALD ADVISERS, LLC | 561,317 | $9,537,000 | 0.36% |
Kazazian Asset Management, LLC | 20,672 | $351,000 | 0.32% |